Live Breaking News & Updates on Serum Phosphorus

Stay updated with breaking news from Serum phosphorus. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Tenapanor Receives FDA Approval for Reducing Serum Phosphorous in CKD

On October 17, 2023, Ardelyx Inc announced the FDA approval of tenapanor (Xphozah) for reducing serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy. ....

United States , Glenn Chertow , Mike Raab , Advisory Committee , Ardelyx Inc , Drug Administration , Renal Drugs Advisory Committee , Stanford University , New Drug Application , Complete Response Letter , P Valuesp Values , Serum Phosphorus , Adult Patients , Ardelyx Receives Complete Response Letter , Treat Hyperphosphatemia , Week Study , Evaluate Tenapanor , End Stage Renal Disease Patients , Adjunctive Therapy , Phosphate Binder , Kidney Week , Chronic Kidney Disease , Serum Phosphate ,

Ardelyx Announces Poster Presentations on XPHOZAH® (tenapanor) at ASN's Kidney Week 2022

/PRNewswire/ Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative. ....

United States , Orange County Convention Center , Fosun Pharma , Prnewswire Ardelyx Inc , American Society Of Nephrology , Kyowa Kirin Co Ltd , Ardelyx Inc , American Society , Kidney Week , Kyowa Kirin , Poster Presentations , Predictive Value , Early Response , Patients Receiving Maintenance , Exhibit Hall , Serum Phosphorus , With Tenapanor , Chronic Kidney Disease , Dialysis With Severe , Reduces Interdialytic Weight Gain , Post Hoc Analysis , Kirin Poster Presentations , Japanese Hemodialysis Patients , Randomized Phase , Tenapanor Added , Phosphate Binders ,

Ardelyx Announces Poster Presentations on XPHOZAH® (tenapanor) at ASN's Kidney Week 2022

WALTHAM, Mass., Oct. 20, 2022 /PRNewswire/ Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develo. ....

United States , Orange County Convention Center , Fosun Pharma , Prnewswire Ardelyx Inc , American Society Of Nephrology , Kyowa Kirin Co Ltd , Ardelyx Inc , American Society , Kidney Week , Kyowa Kirin , Poster Presentations , Predictive Value , Early Response , Patients Receiving Maintenance Dialysis , Exhibit Hall , West Building , Serum Phosphorus , With Tenapanor , Chronic Kidney Disease , Dialysis With Severe Hyperphosphatemia , Reduces Interdialytic Weight Gain , Post Hoc Analysis , Kirin Poster Presentations , Japanese Hemodialysis Patients , Randomized Phase , Tenapanor Added ,

Ardelyx Reports Additional Positive Data Supporting Clinical Utility of Tenapanor at ASN's Kidney Week 2021

/PRNewswire/ Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative. ....

United States , San Antonio , Laura Williams , Derek Forfang , Fosun Pharma , Network Kidney Patient Advisory Council , Clinical Advancement Center , Ardelyx Inc , Renal Associates , Prnewswire Ardelyx Inc , Kidney Patient Advocacy Committee , American Society Of Nephrology Kidney Week , American Society , Nephrology Kidney Week , Patient Advocacy Committee , Kidney Patient Advisory , Reported Experience , Peritoneal Dialysis , Controls Serum Phosphorus , Severe Secondary , Term Safety , Serum Phosphorus , Serum Electrolytes , Kyowa Kirin , Knight Therapeutics ,